Related Experiment Videos
Successful parenteral desensitization to paclitaxel
D M Essayan1, A Kagey-Sobotka, P J Colarusso
1Division of Clinical Immunology, Johns Hopkins Asthma & Allergy Center, Baltimore, MD 21224, USA.
The Journal of Allergy and Clinical Immunology
|January 1, 1996
Summary
This study demonstrates successful desensitization to paclitaxel, a chemotherapy drug, allowing patients to receive treatment safely. Paclitaxel itself, not its formulation, causes allergic reactions.
Area of Science:
- Oncology
- Pharmacology
- Immunology
Background:
- Paclitaxel, a taxane chemotherapy agent, is linked to anaphylactoid reactions.
- Understanding the cause of these hypersensitivity reactions is crucial for patient management.
Observation:
- A case report detailing the successful desensitization of a patient to paclitaxel.
- The desensitization protocol involved serial 10-fold dilutions of paclitaxel.
Findings:
- The patient tolerated paclitaxel infusion post-desensitization without adverse effects.
- Basophil histamine release assays confirmed paclitaxel, not the vehicle, as the allergen.
Implications:
- Parenteral desensitization is an effective strategy for managing paclitaxel hypersensitivity.
- This approach enables continued cancer treatment for patients experiencing allergic reactions.